<DOC>
	<DOC>NCT00453687</DOC>
	<brief_summary>This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.</brief_summary>
	<brief_title>A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.</brief_title>
	<detailed_description>A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 (50, 100 and 200Âµg), formulated with the excipient magnesium stearate, in healthy volunteers.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Healthy male subjects 1855 years old NonSmokers Any subject with breathing problems. High blood pressure and heart abnormalities. Any subjects currently taking prescription and nonprescription medications.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>GSK233705,</keyword>
	<keyword>Magnesium Stearate,</keyword>
</DOC>